Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update.
Yimin Mao, Shiwu Ma, Chenghai Liu...
https://pubmed.ncbi.nlm.nih.gov/38402364/Actively Recruiting
Led by General Hospital of Shenyang Military Region · Updated on 2025-12-18
232
Participants Needed
1
Research Sites
26 weeks
Total Duration
This trial investigates drug-induced liver injury DILI with hyperbilirubinemia, a condition that can cause serious complications like acute liver failure and death. Researchers aim to explore the efficacy and safety of glucocorticoids in treating acute DILI patients with elevated bilirubin levels through a multicenter randomized controlled trial. The study addresses the limited and controversial evidence regarding glucocorticoid use for this condition. A total of 232 patients will be randomly assigned to receive either conventional treatment alone or conventional treatment combined with glucocorticoids. The glucocorticoid treatment involves an initial intravenous dose of methylprednisolone for one week, possibly extended to two, followed by a tapered oral dose over one to three months. Conventional treatments include various liver-supporting drugs, and additional procedures like plasma exchange or liver transplantation may be used if the liver condition worsens. Participants will be closely monitored with evaluations at two and four weeks for liver injury improvement and enzyme levels, along with tracking progressive liver injury, liver failure, transplantation, survival, and adverse events up to three months. The study also explores inflammatory changes and identifies which patients might benefit from glucocorticoid therapy. Total participation spans from enrollment through three months of follow-up.
CONDITIONS
Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia
X
Xingshun Qi
Q
Qianqian Li
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
General Hospital of Shenyang Military Region
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 to 3 months
Participants receive either glucocorticoids combined with conventional treatment or conventional treatment alone for acute drug-induced liver injury. This includes an initial intravenous dose of methylprednisolone for up to two weeks, followed by oral methylprednisolone tapered over 1 to 3 months, alongside other conventional drug therapies.
Weekly visits for up to 4 weeks, then periodic visits during tapering
Duration - Up to 3 months
Participants are monitored for clinical outcomes including liver function improvement, adverse events, and survival up to three months after treatment initiation.
Visits up to 3 months for monitoring
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Yimin Mao, Shiwu Ma, Chenghai Liu...
https://pubmed.ncbi.nlm.nih.gov/38402364/Ping Fang Hu, Pei Qin Wang, Han Chen...
https://pubmed.ncbi.nlm.nih.gov/27426618/Qianqian Li, Yong Lin, Xin Zeng...
https://pubmed.ncbi.nlm.nih.gov/42080196/Feng-Qin Hou, Zheng Zeng, Gui-Qiang Wang
https://pubmed.ncbi.nlm.nih.gov/22806342/Lu Chai, Ran Wang, Rolf Teschke...
https://pubmed.ncbi.nlm.nih.gov/39183394/General Hospital of Shenyang Military Region
Lead Sponsor